SCHEDULE: ARK Investment, Cathie Wood Boost Beam Therapeutics Stake

ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 6 to Schedule 13G, disclosing a combined beneficial ownership of 12.29% in Beam Therapeutics Inc. as of December 31, 2025.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 6 to their Schedule 13G for Beam Therapeutics Inc.
• As of December 31, 2025, the reporting persons beneficially own an aggregate of 12,467,189 shares of Beam Therapeutics Inc. Common Stock.
• This aggregate ownership represents 12.29% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 11,797,335 shares and sole dispositive power over 12,467,189 shares.
• Catherine D. Wood holds shared voting power over 12,029,706 shares and shared dispositive power over 12,467,189 shares.
• ARK Innovation ETF, a series of a Delaware statutory trust, is identified as a client of ARK Investment Management LLC with an interest exceeding 5% in the reported securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as a significant and sustained stake by a prominent, innovation-focused investor like ARK Investment Management signals strong confidence in Beam Therapeutics Inc.'s future prospects and technology.

Positives

• A significant stake (12.29%) held by a prominent investment firm like ARK Investment Management and its CEO, Catherine D. Wood, signals strong conviction in Beam Therapeutics Inc.'s long-term prospects.
• The continued accumulation or maintenance of a substantial position by ARK, as indicated by Amendment No. 6, suggests ongoing confidence in the company's strategic direction and potential.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Beam Therapeutics Inc.'s financial performance or operational outlook, as it is solely a disclosure of beneficial ownership.

Management Comments

• Kellen Carter, Chief Compliance Officer of ARK Investment Management LLC, signed the filing.
• Catherine D. Wood, Chief Executive Officer and Chief Investment Officer, signed the filing.

Industry Context

StockSavvy.ai notes that ARK Investment Management, led by Catherine D. Wood, is known for its focus on disruptive innovation, particularly in sectors like biotechnology and genomics. Their significant and continued stake in Beam Therapeutics Inc., a leader in gene editing, underscores their belief in the transformative potential of the company's technology within the broader biotech industry. This aligns with ARK's investment thesis of identifying companies at the forefront of technological change.

Comparison to Industry Standards

• This filing is a standard Schedule 13G amendment, indicating beneficial ownership above 5%, which is a common disclosure requirement for institutional investors.
• The 12.29% stake is a substantial holding, placing ARK and Catherine D. Wood among the largest institutional shareholders of Beam Therapeutics Inc., comparable to other major asset managers holding significant positions in high-growth biotech firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by ARK Investment Management and Catherine D. Wood may instill confidence among existing shareholders and attract new investors, potentially influencing stock valuation positively.
• Company Management: A large institutional holder like ARK can exert influence on corporate strategy and governance, aligning with their investment thesis for disruptive innovation.

Key Dates

Recommendation

The filing indicates a strong vote of confidence from a prominent institutional investor, which is generally positive. However, as a Schedule 13G, it does not provide new operational or financial data to warrant a 'buy' recommendation. Investors should 'hold' and monitor Beam Therapeutics Inc.'s fundamental performance and ARK's continued involvement.

Keywords

Beam Therapeutics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment Management, ARK Innovation ETF